...the patient was diagnosed with stage IV lung adenocarcinoma...a wide panel genomic sequencing (pan-cancer 1021-gene panel) detected the KIDINS220-ALK fusion….Then, the patient was initiated on alectinib treatment in October 2022. One month later, the CT showed that the tumor lesions had shrunk, and the efficacy was judged as partial response. Moreover, the CEA level of the patient also decreased significantly (Fig. 1B). After 4 months, this patient still benefited and the lesions had shrunk further on CT...our patient rapidly responded to alectinib with remarkable therapeutic effect.